article thumbnail

The Transformative Impact of Radiopharmaceuticals in Medical Imaging

Open Medscience

Radiopharmaceuticals, combining radioactive and pharmaceutical elements, enable precise diagnosis and treatment in nuclear medicine. The post The Transformative Impact of Radiopharmaceuticals in Medical Imaging appeared first on Open Medscience.

article thumbnail

First Participant Treated Using NorthStar Medical Radioisotopes’ Electron Accelerator-produced Copper-67 (Cu-67) in Clarity Pharmaceuticals’ Phase I/IIa Theranostic Clinical Trial Investigating Cu-67 SARTATE for Treatment of Neuroblastoma

Imaging Technology

Administration of the therapeutic dose took place as part of an ongoing Phase I/IIa theranostic clinical trial conducted by Clarity Pharmaceuticals to investigate the safety and efficacy of Cu-67 SARTATE in pediatric patients with high-risk neuroblastoma.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

NorthStar Medical Radioisotopes Announces Promotion of Jason Vinyard, MBA, MHA, to Vice President, Business Development, Therapeutic Technologies

Imaging Technology

He has more than 22 years of operational and commercial expertise in radioisotopes and radiopharmaceuticals. actinium-225 (Ac-225), and drive business development initiatives for NorthStar’s Radiopharmaceutical CDMO/CMO business units. Ac-225 and Cu-67 using environmentally preferable technologies. SPECT franchise.

article thumbnail

NorthStar Medical Radioisotopes Expands Management Team with Appointment of Jean-Noel David, MBA, MS, as Vice President, Operations

Imaging Technology

milla1cf Mon, 04/24/2023 - 14:10 April 24, 2023 — - NorthStar Medical Radioisotopes , LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic and medical imaging applications, has announced the appointment of Jean-Noel David , MBA, MS, as Vice President, Operations.

Medical 81
article thumbnail

NorthStar Medical Radioisotopes Announces Supply Agreement with Nucleus RadioPharma for Alpha-emitting Therapeutic Radioisotope Actinium-225 (Ac-225)

Imaging Technology

Nucleus will use NorthStar’s Ac-225 for their customers’ radioligand pharmaceutical programs. Ac-225 and copper-67 (Cu-67) for advancing clinical research and commercial radiopharmaceutical therapy products. Ac-225 to Nucleus. The Company will use its electron accelerator technology to produce n.c.a.

Medical 63
article thumbnail

NorthStar Medical Radioisotopes Provides Updates on Corporate Progress and Upcoming Milestones

Imaging Technology

Mr. Merrick continued, “Demand for therapeutic radiopharmaceuticals is increasing rapidly. NorthStar has further deepened and broadened our business platform with the recent establishment of a full-scale radiopharmaceutical CDMO/CMO services unit. Ac-225 using advanced, environmentally preferable electron accelerator technology.

Medical 82
article thumbnail

NorthStar Medical Technologies, LLC Appoints Frank Scholz, Ph.D., as President and Chief Executive Officer

Imaging Technology

milla1cf Mon, 06/19/2023 - 19:27 June 19, 2023 — NorthStar Medical Technologies, LLC , a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, today announced the appointment of Frank Scholz, Ph.D.,

Medical 80